Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Subscribe To Our Newsletter & Stay Updated
